2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

2:30PM-4:00PM: Abstract Number: 945

Anti-Hmgcr Antibodies As Specific Marker for Immune Mediated Necrotizing Myopathies

Muscle Biology, Myositis and Myopathies I

2:30PM-4:00PM: Abstract Number: 981

Anti-IL-17A Treatment Blocks Inflammation, Destruction and New Bone Formation in Experimental Spondyloarthritis in HLA-B27 Transgenic Rats

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 986

Application of New EULAR Definitions of Remission in SLE: Durable 1-Year Remission Is Rare

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

2:30PM-4:00PM: Abstract Number: 916

Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database

Fibromyalgia: Insights Into Diagnostic Criteria and Symptom Epidemiology

2:30PM-4:00PM: Abstract Number: 918

Assessment of the Temporal Variation of the Fibromyalgia Patient Profile Between 2005 and 2013: Do Guidelines Inform Clinical Care?

Fibromyalgia: Insights Into Diagnostic Criteria and Symptom Epidemiology

2:30PM-4:00PM: Abstract Number: 980

Association of Platelet Endothelial Cell Adhesion Molecule-1 and ß1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 948

Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response

Muscle Biology, Myositis and Myopathies I

2:30PM-4:00PM: Abstract Number: 919

Automated Case Identification of Lupus from an Electronic Health Record Using Novel Informatics Approaches

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 991

CaMK4 Facilitates Recruitment of IL-17 Producing Cells to Target Organs through the CCR6/CCL20 Axis in Th17-Driven Inflammatory Diseases

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 955

Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)

Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 982

CD4+CD146+ T Cells: The Primed IL-17 Secreting Cells in the Pathogenesis of Psoriatic Arthritis

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 968

Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 903

CGEN-15001, a Novel B7-like Protein, Controls Inflammation in a Translational Rheumatoid Arthritis (RA) Assay and Induces Treg Driven Long-Term Remission in an Autoimmune Disease Model

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

2:30PM-4:00PM: Abstract Number: 917

Chronic Widespread Pain in Adolescents Is Highly Associated to Stress and Anxiety

Fibromyalgia: Insights Into Diagnostic Criteria and Symptom Epidemiology

2:30PM-4:00PM: Abstract Number: 905

Citrullinated Epithelial-Derived Neutrophil-Activating Peptide 78 (ENA-78/CXCL5) Induces Monocyte Migration Via JNK and NFκB Signaling Pathways

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].